We all have a unique face, fingerprint, voice and signature, so why wouldn’t we have a unique response to the medicine and treatments we receive?
Risk-benefit determinations: FDA finalizes long-awaited guidance for drugmakers
The FDA on Thursday finalized guidance from September 2021 on the agency’s benefit-risk assessments for new drugs and biologics, spelling out its most pertinent considerations